Cancer researchers believe that proteomics is revolutionizing the way cancer and other major illnesses are detected. With the discovery of new proteins and mapping of the human genome, proteomics may be the vanguard of a new generation of tools used to detect cancer during its early phases and to tailor therapy for individual patients.
Incorporating proteomics into medical evaluation is helping to advance the cancer research field, from early diagnosis to the identification of high-risk patients, according to Lance Liotta, MD, PhD, of the CCR NCI and Co-Director with Emanuel Petricoin PhD of the NIH/NCI-FDA Clinical Proteomics Program.
Multiple High-Resolution Serum Proteomic Patterns for Ovarian Cancer Detection
The infant process of serum proteomic pattern diagnostics has generally relied on low-resolution mass spectrometry to detect a protein pattern that would signal disease. In a study presented by researchers at the NCI/FDA Clinical Proteomics Program, researchers extended the analysis to a higher resolution method using multiple accurate protein patterns to detect cancer.
Using a well-controlled serum study from 248 women at risk for ovarian cancer, researchers extended the original pattern analysis to a higher resolution based on multiple patterns. The results showed 59 different patterns that were more than 85 percent accurate in disease diagnosis, four of which were 100 percent accurate. Researchers report that multiple proteomic patterns do exist within human se
Contact: Aimee Frank
American Association for Cancer Research